Coherus Oncology, Inc.
CHRS
$1.42
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.44% | 10.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.44% | 10.17% | |||
| Cost of Revenue | -5.71% | 8.71% | |||
| Gross Profit | -2.38% | 10.87% | |||
| SG&A Expenses | 9.97% | -7.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.51% | 4.13% | |||
| Operating Income | 16.47% | -2.48% | |||
| Income Before Tax | 20.31% | -4.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.31% | -4.11% | |||
| Earnings from Discontinued Operations | -115.99% | -3.14% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.82% | -5.94% | |||
| EBIT | 16.47% | -2.48% | |||
| EBITDA | 16.78% | -2.71% | |||
| EPS Basic | 10.14% | -2.29% | |||
| Normalized Basic EPS | 25.50% | 0.44% | |||
| EPS Diluted | 10.14% | -2.29% | |||
| Normalized Diluted EPS | 25.50% | 0.44% | |||
| Average Basic Shares Outstanding | 13.32% | 3.56% | |||
| Average Diluted Shares Outstanding | 13.32% | 3.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||